Daiichi Sankyo | GenomeWeb

Daiichi Sankyo

MolecularMD's assay will be used to select patients for a Phase II clinical trial in Europe to test an unspecified oncology therapy from Daiichi Sankyo.

The large PGx analysis might provide welcome data for those already supportive of genotyping in the context of warfarin, but will it convince detractors?

NEW YORK (GenomeWeb) – Agendia today announced a new deal with Daiichi Sankyo to use Agendia's oncology biomarker technology to evaluate new drugs from the Japanese drug firm currently in clinical trials.

By Adam Bonislawski
Biotech firm KineMed said this week that it has signed a research collaboration agreement with Pfizer to investigate therapies for metabolic diseases, particularly type 2 diabetes.

Roche said this week that European regulators have cleared its Cobas BRAF mutation companion diagnostic for the melanoma drug Zelboraf (vemurafenib).

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – The US Food and Drug Administration has approved Roche's drug and companion diagnostic test for late-stage unresectable melanoma.

Plexxikon is seeking marketing approval for PLX4032 for the treatment of metastatic melanoma in patients harboring the BRAF V600 mutation. Simultaneously, Roche Molecular Diagnostics has submitted a premarket approval application to the FDA for its Cobas 4800 BRAF V600 Mutation Test.

The Japanese drug firm will use Kinaxo's Cellular Target Profiling, KinAffinity, and PhosphoScout products.

Findings in a NEJM study this week challenged previously reported data that alleles in the CYP2C19 gene can limit how certain carriers of the polymorphisms respond to Plavix.

Pages

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.